Xsolla Partner Network Enhances Developer and Creator Experience in Marketing With New Features and Data Insights
12.3.2025 15:00:00 EET | Business Wire | Press release
Xsolla, a leading global video game commerce company, introduces significant updates to the Xsolla Partner Network, an advanced affiliate marketing engine designed to connect game developers with content creators. These updates enhance the experience for both developers and creators by introducing new interaction tools, expanded data accessibility, and deeper integrations with the Xsolla Rainmaker platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250312640811/en/
Graphic: Xsolla
The growing influence of content creators on platforms like YouTube, Twitch, and TikTok has reshaped game marketing strategies. Developers increasingly seek streamlined ways to discover, manage, and measure creator partnerships. The Xsolla Partner Network addresses this demand by providing an all-in-one solution for creating and scaling performance-based campaigns, now with added tools to enhance usability and campaign success.
New Xsolla Partner Network updates significantly benefit developers and creators, enhancing their ability to collaborate effectively and succeed in their goals.
For developers, the platform now offers:
- Enhanced search functionality to discover, compare, and invite creators who best align with campaign goals
- Detailed creator profiles with insights such as concurrent viewer metrics, games played, and campaign performance, enabling developers to make informed decisions
- Integration with Xsolla Rainmaker data from Twitch and YouTube Gaming, providing robust analytics like streamer views, follower counts, and game-specific performance data for data-driven decision-making
- Streamlined collaboration tools, including direct distribution of promo codes, tracking links, and game keys
- A flexible revenue share model, allowing developers to set customizable commission rates for creators driving successful transactions
Creators gain access to a comprehensive creator toolkit designed to simplify campaign management and accelerate growth. The redesigned interface provides intuitive tools and features that make managing campaigns, engaging audiences, and enhancing content creation easier. By removing the 50-subscriber minimum threshold, the platform is now accessible to micro creators, enabling them to kickstart their careers.
Additional features for creators include:
- Real-time performance tracking, offering insights into campaign results.
- User-friendly account navigation, simplifying platform usage.
- Opportunities to partner directly with game developers, helping creators grow their audience and monetize their work by driving sales for games and in-game content featured at Xsolla Mall.
- Creator sites at Xsolla Mall enable creators to resell digital content, showcase campaign details, collect donations, and share links to all social media platforms to increase visibility.
- Overlays, providing game-branded promotional graphics and animations for live streams to boost engagement and drive awareness.
- Chatbot isdesigned to share tracking links and promo codes in real-time chats during gameplay, reward viewers, and engage the community.
With these updates, the Xsolla Partner Network empowers developers and creators to collaborate seamlessly, unlocking new opportunities for success in the evolving landscape of game marketing.
“The Xsolla Partner Network has always been a powerful tool for developers to grow their games and for creators to monetize their passion,” said Chris Hewish, Chief Strategy Officer at Xsolla. “With these new features, we enable seamless collaboration between developers and creators, ensuring both can achieve their goals more effectively.”
Xsolla Partner Network’s updates are now available to developers, publishers, and creators worldwide. To learn more, visit: https://xsolla.pro/rws25pn
About Xsolla
Xsolla is a leading global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For more information, visit xsolla.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250312640811/en/
Contacts
Media Contact
Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom